Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

2020; American Medical Association; Volume: 156; Issue: 12 Linguagem: Inglês

10.1001/jamadermatol.2020.3260

ISSN

2168-6084

Autores

Kristian Reich, Kenji Kabashima, Ketty Peris, Jonathan I. Silverberg, Lawrence F. Eichenfield, Thomas Bieber, Aleksandra Kaszuba, Jill Kolodsick, Fan Emily Yang, Margaret Gamalo, Dennis Brinker, Amy M. DeLozier, Jonathan Janes, Fabio P. Nunes, Jacob P. Thyssen, Eric L. Simpson,

Tópico(s)

Food Allergy and Anaphylaxis Research

Resumo

Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy studies.

Referência(s)